Zanubrutinib Oral Product
Sponsors
UMC Utrecht, PETHEMA Foundation
Conditions
Chronic Lymphocytic LeukemiaMonoclonal Gammopathy of Uncertain SignificanceSmall Lymphocytic Lymphoma
Phase 2
Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy
Active, not recruitingNCT05939037
Start: 2024-03-01End: 2029-03-01Target: 35Updated: 2026-05-08
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingNCT06544785
Start: 2024-09-02End: 2032-05-31Target: 106Updated: 2026-06-25